logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us
logotype
logotype
  • Home
  • About Us
  • Events
    • Upcoming Conferences
    • Past Conferences
  • Event Support
  • Careers
  • Contact Us

Tag: pharmareglatory

August 19, 2024
by info@virtueinsight.comNews

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Biogen has completed the acquisition of Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). “We are very excited about the addition of felzartamab into our...
read more
July 4, 2024
by info@virtueinsight.comNews

AbbVie completes acquisition of Celsius Therapeutics for $250m

US-based biopharmaceutical company AbbVie has acquired Celsius Therapeutics, a biotechnology company developing therapies for inflammatory diseases, for $250m. The strategic move expands AbbVie’s footprint in the treatment of inflammatory diseases, adding a potentially transformative...
read more
July 4, 2024
by info@virtueinsight.comNews

Sanofi and Belharra forge $700m partnership for immunological diseases

  Belharra Therapeutics has announced that it has entered a strategic partnership with global powerhouse Sanofi to spur the development of small molecule therapies for immunological diseases. Under the terms of the agreement, the San Diego, California-based next-generation...
read more
July 4, 2024
by info@virtueinsight.comNews

ANI Pharmaceuticals to Acquire Alimera Sciences

  ANI Pharmaceuticals and Alimera Sciences had announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per...
read more
July 4, 2024
by info@virtueinsight.comNews

EQT Acquires Majority Stake in CluePoints

EQT is pleased to announce that the EQT Healthcare Growth Strategy and the EQT Growth Fund have agreed to acquire a majority stake in CluePoints  with meaningful reinvestment from the management team and existing shareholders Summit Partners and Clinimetrics SA, which was also a...
read more
May 13, 2024
by info@virtueinsight.comNews

AstraZeneca Withdraws Covid-19 Vaccine Worldwide

Anglo-Swedish drugmaker AstraZeneca  on Wednesday announced the global withdrawal of its Covid-19 vaccine Vaxzevria. Demand for AstraZeneca’s Vaxzevria vaccine began tapering off as new vaccines tailored to specific Covid variants have emerged, the pharmaceutical company said in a...
read more
May 13, 2024
by info@virtueinsight.comNews

AbbVie to buy Landos Biopharma for up to $212M

  AbbVie Inc. and Landos Biopharma, Inc.  had announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos’ lead...
read more
May 13, 2024
by info@virtueinsight.comNews

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion

ONO Pharmaceutical and Deciphera Pharmaceuticals had announced that on April 29, 2024 ,ONO and Deciphera entered into a definitive merger agreement under which ONO will acquire all outstanding shares of Deciphera common stock for US $ 25.60 per share in cash through a tender offer...
read more
May 9, 2024
by info@virtueinsight.comNews

Lilly Acquires New Injectable Medicine Manufacturing Facility from Nexus Pharmaceuticals

Eli Lilly and Company  and Nexus Pharmaceuticals, today announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry. “The acquisition of this state-of-the-art facility underscores our...
read more
May 9, 2024
by info@virtueinsight.comNews

AstraZeneca Withdraws Covid-19 Vaccine Worldwide

Anglo-Swedish drugmaker AstraZeneca  on Wednesday announced the global withdrawal of its Covid-19 vaccine Vaxzevria. Demand for AstraZeneca’s Vaxzevria vaccine began tapering off as new vaccines tailored to specific Covid variants have emerged, the pharmaceutical company said in a...
read more
  • 1
  • 2
  • 3
  • 4
logotype

We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Facebook-fTwitterYoutubeLinkedin-inInstagramPinterest

Quick Links

About us
Contact us
Event Support
Careers
Privacy Policy
Terms & Conditions

Subscribe to our newsletter

    © 2025 Virtue Insight. All rights reserved.